Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Precision medicine for patients with lymphoma; the Bloodwise Precision Medicine for Aggressive Lymphomas (PMAL) consortium

Bridgin Merron, Shamim Kazmi-Stokes, Thomas Cummin, Sharon Barrans, Shamzah Araf, Koorosh Korfi, Laura D Lopez Pascua, Josh Caddy, Kelly Cozens, Francesco Cucco, Rahman Uddin, Chulin Sha, Reuben Tooze, Gareth Griffiths, Ming Qing Du, Cathy Burton, David Westhead, Jude Fitzgibbon, Anna Schuh, Andrew Davies and Peter Johnson
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.19-2-s100
Clin Med March 2019
Bridgin Merron
ASouthampton Clinical Trials Unit
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shamim Kazmi-Stokes
BCancer Research UK Centre, University of Southampton, Southampton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Cummin
BCancer Research UK Centre, University of Southampton, Southampton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon Barrans
CHMDS, Leeds Cancer Centre, Leeds
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shamzah Araf
DCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koorosh Korfi
DCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura D Lopez Pascua
EDepartment of Oncology, Division of Molecular Histopathology, University of Oxford, Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josh Caddy
ASouthampton Clinical Trials Unit
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly Cozens
ASouthampton Clinical Trials Unit
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Cucco
FUniversity of Cambridge, Cancer Research UK Centre, Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rahman Uddin
GSchool of Molecular and Cellular Biology, University of Leeds, Leeds, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chulin Sha
GSchool of Molecular and Cellular Biology, University of Leeds, Leeds, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reuben Tooze
GSchool of Molecular and Cellular Biology, University of Leeds, Leeds, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gareth Griffiths
ASouthampton Clinical Trials Unit
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming Qing Du
FUniversity of Cambridge, Cancer Research UK Centre, Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cathy Burton
CHMDS, Leeds Cancer Centre, Leeds
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Westhead
GSchool of Molecular and Cellular Biology, University of Leeds, Leeds, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jude Fitzgibbon
DCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Schuh
EDepartment of Oncology, Division of Molecular Histopathology, University of Oxford, Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Davies
BCancer Research UK Centre, University of Southampton, Southampton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Johnson
BCancer Research UK Centre, University of Southampton, Southampton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Aims

While conventional therapy is curative for most patients with high grade lymphomas, there is considerable heterogeneity in this diagnosis, with scope to refine treatment according to the precise molecular phenotype. This is increasingly used to guide specific therapy and to predict outcomes. The Precision Medicine for Aggressive Lymphomas (PMAL) consortium is a national multi-partner network, established to develop robust predictive molecular assays for patients with high grade lymphomas and to optimise their treatment through trials of novel targeted therapy based on the results.

Methods

Biopsy samples from patients with lymphoma are studied by genomic, transcriptomic, molecular and immunophenotypic analysis, to establish their precise sub-type and to suggest options for targeted therapy. In parallel, studies of circulating free DNA are used to track actionable somatic mutations and monitor the response to therapy, and sequential biopsies from patients with recurrent disease are analysed to examine clonal emergence and evolution. A network of four laboratories undertakes this work, linked to a portfolio of clinical trials for patients with newly diagnosed or recurrent disease, coordinated by the Southampton Clinical Trials Unit. Complex bioinformatics analysis is used to refine the classification of the diseases according to detailed biological understanding and its impact on pathological behaviour.

Results

Over 1,100 patients have had whole transcriptome analysis performed in the REMoDL-B study, and the results linked to somatic deoxyribonucleic acid changes. This confirmed the existence of at least three distinct subgroups (germinal centre (GCB), activated B-cell like (ABC) and unclassifiable) within the overall diagnosis of diffuse large B-cell lymphoma, showing differential responsiveness to therapy including a proteasome inhibitor, bortezomib. The mutational frequency of MYD88, PRDM1, CD79B was higher in ABC, while mutations in CREBBP, EZH2, DDX3X, FAS and KMT2D were more frequent in GCB. There was no difference in 30-month progression-free survival (PFS) in the combined GCB + ABC population between RB-CHOP and R-CHOP; 74.3% and 70.1% respectively. Bortezomib did not significantly affect PFS in either GCB or ABC, however some patients with ABC and low international prognostic index had a significantly better PFS with the addition of bortezomib. Retrospective application of a Burkitt-like molecular classifier identified a group of GCB patients (17%) with a particularly poor prognosis and higher proportion of c-MYC gene rearrangements than other GCBs. With the addition of bortezomib, there was a trend towards improved PFS in this sub-group.

This targeted approach is now being applied in a new Cancer Research UK funded trial of first-line therapy, ACCEPT. The addition of a Bruton's tyrosine kinase inhibitor, acalabrutinib, to standard chemo-immunotherapy, stratified according to their mRNA profile is being examined. Characterisation of the microenvironment by gene expression profile is being used to analyse the results of new immunotherapy studies for patients with recurrent disease. The immune checkpoint inhibitor atezolizumab, is being tested in combination with conventional salvage chemotherapy in the ARGO trial. Broad genomic panel testing is being piloted to determine the utility of prospective identification of somatic changes as a guide to therapy. In the MaPLe study over 2,000 routine biopsies have been analysed, and prospective screening is underway to identify cases bearing an activating mutation in the epigenetic modifying gene EZH2, in support of a trial of the EZH2 inhibitor tazemetostat. The overall incidence of mutations is 10–15%, with early evidence to suggest that these may predict responsiveness to the inhibitor.

Conclusion

The PMAL consortium continues to refine the diagnostic platforms of high grade lymphoma. Analysis of the expanding genotype/phenotype database is being used to inform patient treatment decisions and shape a portfolio of future clinical trials, in collaboration with a number of pharma company partners.

Conflict of interest statement

Research funding to the PMAL consortium has been provided by Janssen, Roche, Epizyme and Acerta.

  • © Royal College of Physicians 2019. All rights reserved.
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Precision medicine for patients with lymphoma; the Bloodwise Precision Medicine for Aggressive Lymphomas (PMAL) consortium
Bridgin Merron, Shamim Kazmi-Stokes, Thomas Cummin, Sharon Barrans, Shamzah Araf, Koorosh Korfi, Laura D Lopez Pascua, Josh Caddy, Kelly Cozens, Francesco Cucco, Rahman Uddin, Chulin Sha, Reuben Tooze, Gareth Griffiths, Ming Qing Du, Cathy Burton, David Westhead, Jude Fitzgibbon, Anna Schuh, Andrew Davies, Peter Johnson
Clinical Medicine Mar 2019, 19 (Suppl 2) s100-s101; DOI: 10.7861/clinmedicine.19-2-s100

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Precision medicine for patients with lymphoma; the Bloodwise Precision Medicine for Aggressive Lymphomas (PMAL) consortium
Bridgin Merron, Shamim Kazmi-Stokes, Thomas Cummin, Sharon Barrans, Shamzah Araf, Koorosh Korfi, Laura D Lopez Pascua, Josh Caddy, Kelly Cozens, Francesco Cucco, Rahman Uddin, Chulin Sha, Reuben Tooze, Gareth Griffiths, Ming Qing Du, Cathy Burton, David Westhead, Jude Fitzgibbon, Anna Schuh, Andrew Davies, Peter Johnson
Clinical Medicine Mar 2019, 19 (Suppl 2) s100-s101; DOI: 10.7861/clinmedicine.19-2-s100
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Aims
    • Methods
    • Results
    • Conclusion
    • Conflict of interest statement
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Inaccessible back: frustration and misery of lonely patients
  • Methylation of somatostatin receptor 2 gene in neuroendocrine tumours as a predictor of tumour response to peptide receptor radionuclide therapy
  • Viral and other infections in community and primary hypothyroidism – cause or coincidence?
Show more Research and innovation

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians